BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 22524574)

  • 1. Sorafenib in combination with transarterial chemoembolization and bronchial arterial chemoinfusion in the treatment of hepatocellular carcinoma with pulmonary metastasis.
    Duan F; Wang MQ; Liu FY; Wang ZJ; Song P; Wang Y
    Asia Pac J Clin Oncol; 2012 Jun; 8(2):156-63. PubMed ID: 22524574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib.
    Pinter M; Hucke F; Graziadei I; Vogel W; Maieron A; Königsberg R; Stauber R; Grünberger B; Müller C; Kölblinger C; Peck-Radosavljevic M; Sieghart W
    Radiology; 2012 May; 263(2):590-9. PubMed ID: 22438359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma.
    Park JW; Koh YH; Kim HB; Kim HY; An S; Choi JI; Woo SM; Nam BH
    J Hepatol; 2012 Jun; 56(6):1336-42. PubMed ID: 22314421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study.
    Bai W; Wang YJ; Zhao Y; Qi XS; Yin ZX; He CY; Li RJ; Wu KC; Xia JL; Fan DM; Han GH
    J Dig Dis; 2013 Apr; 14(4):181-90. PubMed ID: 23324079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma.
    Kudo M; Imanaka K; Chida N; Nakachi K; Tak WY; Takayama T; Yoon JH; Hori T; Kumada H; Hayashi N; Kaneko S; Tsubouchi H; Suh DJ; Furuse J; Okusaka T; Tanaka K; Matsui O; Wada M; Yamaguchi I; Ohya T; Meinhardt G; Okita K
    Eur J Cancer; 2011 Sep; 47(14):2117-27. PubMed ID: 21664811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of hepatic arterial infusion chemotherapy as an alternative to sorafenib in advanced hepatocellular carcinoma.
    Jeong SW; Jang JY; Lee JE; Lee SH; Kim SG; Cha SW; Kim YS; Cho YD; Kim HS; Kim BS; Kim KH; Kim YJ
    Asia Pac J Clin Oncol; 2012 Jun; 8(2):164-71. PubMed ID: 22524575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes.
    Yoon SM; Lim YS; Won HJ; Kim JH; Kim KM; Lee HC; Chung YH; Lee YS; Lee SG; Park JH; Suh DJ
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):2004-11. PubMed ID: 21621346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study of local three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for patients with stage III hepatocellular carcinoma.
    Li B; Yu J; Wang L; Li C; Zhou T; Zhai L; Xing L
    Am J Clin Oncol; 2003 Aug; 26(4):e92-9. PubMed ID: 12902905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of transarterial chemoembolization plus sorafenib for hepatocellular carcinoma with portal venous tumour thrombus.
    Pan T; Li XS; Xie QK; Wang JP; Li W; Wu PH; Zhao M
    Clin Radiol; 2014 Dec; 69(12):e553-61. PubMed ID: 25304928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factors.
    Song T; Zhang W; Wu Q; Kong D; Ma W
    Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1233-8. PubMed ID: 21941188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma.
    Peng Z; Chen S; Xiao H; Wang Y; Li J; Mei J; Chen Z; Zhou Q; Feng S; Chen M; Qian G; Peng S; Kuang M
    Radiology; 2019 Jul; 292(1):237-247. PubMed ID: 31135299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy.
    Lencioni R
    Crit Rev Oncol Hematol; 2012 Aug; 83(2):216-24. PubMed ID: 22142656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib and cisplatin/doxorubicin (PLADO) in pediatric hepatocellular carcinoma.
    Schmid I; Häberle B; Albert MH; Corbacioglu S; Fröhlich B; Graf N; Kammer B; Kontny U; Leuschner I; Scheel-Walter HG; Scheurlen W; Werner S; Wiesel T; von Schweinitz D
    Pediatr Blood Cancer; 2012 Apr; 58(4):539-44. PubMed ID: 21922643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation.
    Chapman WC; Majella Doyle MB; Stuart JE; Vachharajani N; Crippin JS; Anderson CD; Lowell JA; Shenoy S; Darcy MD; Brown DB
    Ann Surg; 2008 Oct; 248(4):617-25. PubMed ID: 18936575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical observation of the treatment with combination of transcatheter arterial chemoembolization and sorafenib for hepatocellular carcinoma with lung metastasis].
    Duan F; Wang MQ; Liu FY; Wang ZJ; Song P
    Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):716-8. PubMed ID: 20021873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic analysis of transarterial chemoembolization combined with a traditional Chinese herbal medicine formula for treatment of unresectable hepatocellular carcinoma.
    Yu Y; Lang QB; Chen Z; Li B; Yu CQ; Zhu DZ; Huang XQ; Zhai XF; Ling CQ
    Chin Med J (Engl); 2009 Sep; 122(17):1990-5. PubMed ID: 19781383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
    Abou-Alfa GK; Schwartz L; Ricci S; Amadori D; Santoro A; Figer A; De Greve J; Douillard JY; Lathia C; Schwartz B; Taylor I; Moscovici M; Saltz LB
    J Clin Oncol; 2006 Sep; 24(26):4293-300. PubMed ID: 16908937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transarterial chemotherapy alone versus transarterial chemoembolization for hepatocellular carcinoma: a randomized phase III trial.
    Okusaka T; Kasugai H; Shioyama Y; Tanaka K; Kudo M; Saisho H; Osaki Y; Sata M; Fujiyama S; Kumada T; Sato K; Yamamoto S; Hinotsu S; Sato T
    J Hepatol; 2009 Dec; 51(6):1030-6. PubMed ID: 19864035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective phase 2 multicenter study for the efficacy of radiation therapy following incomplete transarterial chemoembolization in unresectable hepatocellular carcinoma.
    Choi C; Koom WS; Kim TH; Yoon SM; Kim JH; Lee HS; Nam TK; Seong J
    Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1051-60. PubMed ID: 25303890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transarterial injection of recombinant human type-5 adenovirus H101 in combination with transarterial chemoembolization (TACE) improves overall and progressive-free survival in unresectable hepatocellular carcinoma (HCC).
    Lin XJ; Li QJ; Lao XM; Yang H; Li SP
    BMC Cancer; 2015 Oct; 15():707. PubMed ID: 26470869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.